Product Description
Mechanisms of Action: Apoptosis Inhibitor,VEGF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mannkind
Company Location: WESTLAKE VILLAGE CA 91362
Company CEO: Michael E. Castagna
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|